Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Febuxostat versus allopurinol for oxidative stress in asymptomatic hyperuricemia with chronic kidney disease
ChiCTR1800020310Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Qingdao University
- Start
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of febuxostat and allopurinol in hyperuricemia and chronic kidney disease (CKD) (3 arms), sponsored by The Affiliated Hospital of Qingdao University. Primary endpoints: serum uric acid, high sensitivity C-reactive protein and 3 more. Started Sep 2018; status: recruiting.
02
Drugs
febuxostatallopurinol
03
Conditions
hyperuricemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on ChiCTR1800020310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020310.